3N Diagnostics, the manufacturer of a new breast cancer test, have announced the launch of their new subsidiary called 3N Diagnostics (IRL) Ltd., which is located at CoLab in Letterkenny.
Their test is the newly CE Marked Avisio FOXC1 immunohistochemistry (IHC) breast cancer test for basal-like breast cancer.
3N Diagnostics (IRL) has been set up to maintain a long-term presence in the European single market and to support 3N Diagnostics’ international expansion as demand for its business grows.
This news has been welcomed by CoLab Director Patrick Donaghy. He said; “We are delighted to welcome 3N Diagnostics to CoLab and to be given the chance to assist them in their international expansion. CoLab is home to over 50 internationally focused high technology companies employing more than 250 people.”
Roberto Fagnani, PhD, CEO of 3N Diagnostics, said; “We are pleased with the prompt assistance CoLab has provided to us in this endeavour. We look forward to growing our European presence and to assisting our US sister company Onconostic Technologies, Inc. in its product launch effort. Our first product, Avisio FOXC1 IHC for breast cancer, has obtained CE Marking designation and is being introduced to the European market.”
Gerard Burke, member of 3N Diagnostics’ (IRL) Board of Directors, said; “3N Diagnostics brings the innovative Avisio FOXC1 breast cancer test to Letterkenny, a centre in the Republic of Ireland well known for successful start-up companies”.
